SINOCELLTECH GROUP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.8 CNY | +4.23% |
|
+24.47% | -13.12% |
| Apr. 18 | Sinocelltech Forecasts Return to Profit in Q1 | MT |
| Apr. 18 | China stocks track Asian markets higher | RE |
| Sales 2024 * | 2.72B 376M | Sales 2025 * | 3.55B 490M | Capitalization | 20B 2.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 283M 39.06M | Net income 2025 * | 441M 60.86M | EV / Sales 2024 * | 7.35 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.63 x |
| P/E ratio 2024 * |
71.3
x | P/E ratio 2025 * |
45.4
x | Employees | 2,313 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 19.48% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.38% | ||
| 1 week | +19.41% | ||
| Current month | +9.54% | ||
| 1 month | +4.56% | ||
| 3 months | +2.14% | ||
| 6 months | -2.81% | ||
| Current year | -16.65% |
1 week
36.80
45.43
1 month
36.8045.43
Current year
34.3455.87
1 year
34.3479.46
3 years
34.3497.21
5 years
34.34103.99
10 years
34.34103.99
| Managers | Title | Age | Since |
|---|---|---|---|
Liang Zhi Xie
CEO | Chief Executive Officer | 58 | 07-04-22 |
Jie Ma
DFI | Director of Finance/CFO | 52 | 23-04-24 |
Gui Fen Zhao
BRD | Director/Board Member | 57 | 17-07-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Chuan Wang
BRD | Director/Board Member | 69 | 19-03-16 |
Zhi Guo Su
BRD | Director/Board Member | 70 | 19-03-16 |
Wei Qiang Han
BRD | Director/Board Member | 70 | 22-05-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 46.8 | +4.23% | 4 096 231 |
| 24-04-22 | 44.9 | +3.38% | 3,511,989 |
| 24-04-19 | 43.43 | +1.38% | 3,894,521 |
| 24-04-18 | 42.84 | +14.82% | 6,026,457 |
| 24-04-17 | 37.31 | +0.81% | 1,829,041 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
Sinocelltech Group Ltd is a China-based company mainly engaged in the research, development and industrialization of biopharmaceutical products. The Company focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The Company is also engaged in asset leasing business and payment collection business.
Calendar
2024-04-23
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
44.9
CNY
Average target price
64
CNY
Spread / Average Target
+42.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.65% | 2.76B | |
| +2.49% | 96.73B | |
| -0.03% | 21.31B | |
| -16.61% | 21.21B | |
| -5.80% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- 688520 Stock
